Alberta Children's Hospital
Calgary, Alberta, T3B 6A8, Canada
Location status: Recruiting
Location contact
Kara Murias
CONTACT
Kara r Murias, MD/PhD
CONTACT
NCT Number: NCT04532190
Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.
Interested in participating?
Request Info9 year–15 year
All sexes
Interventional
Not applicable
Calgary, Alberta, T3B 6A8, Canada
Location status: Recruiting
Kara Murias
CONTACT
Kara r Murias, MD/PhD
CONTACT
Background & Rationale Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. It has an estimated prevalence of 5% in children. Usually, ADHD in children is treated with stimulant medications, such as methylphenidate. However, these pharmacotherapy treatments have numerous unwanted side effects, including sleep disturbances, appetite changes, and emotional lability, and do not prove to be effective in every case.
A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation which involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas. In turn, rTMS leads to positive long-term changes in neurochemical activity, and while studies are limited, some have shown that rTMS can reduce ADHD symptoms in adolescents with ADHD.
Methods Design: Open label TMS trial Primary Outcome: To examine the effect of active rTMS to the right prefrontal cortex on attention as measured by the TEACh-2
Outline:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Repetitive transcranial magnetic stimulation (rTMS)
Time frame: Baseline to week 5
Test of everyday attention in children - 2. Direct assessment of attention abilities in children.
Time frame: 5 weeks and 52 weeks.
Parent reporting of ADHD symptom severity
Time frame: Baseline to week 5
Self reporting of quality of life
University of Calgary
Other
Acronym: FAST-ADHD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07592390
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Tubarão, Santa Catarina, Brazil
View Trial DetailsNCT06967857
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Frankfurt, Germany
View Trial DetailsNCT07731893
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07716072
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Singapore
View Trial Details